


IMMUNO-ONCOLOGY

JUNE 3, 2020



Date	Time	Track	Presentation Title	Speaker
3-Jun	06:00 - 07:00 AM	Immunotherapeutic Modalities	Keynote Presentation: Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment	Sumit K. Subudhi, MD, PhD Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
3-Jun	07:00 - 08:00 AM	Immunotherapeutic Modalities	High throughput biomarker profiling for immunology research using MILLIPLEX® assays	Jenny Koenitzer, PhD Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA Yan Nikhamin, MS, MBA Biomarkers & Cytometry Specialistm MilliporeSigma
3-Jun	08:00 - 09:00 AM	Development and Clinical Applications of Cancer Immunotherapies	Keynote Presentation: It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology	Alexander David Borowsky, MD Professor, Pathology and Laboratory Medicine, Center for Immunology and Infectious Disease and UC Davis Comprehensive Cancer Center
3-Jun	09:30 - 10:30 AM	Latest Trends in Immuno-Oncology	Keynote Presentation: The Importance of Tissue Chemistry in Immunity-Oncology	Thomas M. Grogan, MD Professor Emeritus of Pathology, University of Arizona; Founder and Chief Scientific Advisor Emeritus, Ventana Medical Systems, Inc., a division of Roche
3-Jun	11:00 - 12:00 PM	Immunotherapeutic Modalities	Keynote Presentation: Combinatorial Approaches to Immunotherapy: Melanoma as the Example	Stephen Hodi, MD Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
3-Jun	12:00 - 01:00 PM	Latest Trends In Immuno-Oncology	How multiplexed imaging reveals key insights into the tumor microenvironment to inform treatment and improve outcomes	Paul Goodwin President, The Histochemical Society; Science Director for Cytiva Fiona Ginty Technology Manager for Biosciences, GE Research Center Prachi Bogetto Diagnostics Segment Leader/Marketing Leader Cell Analysis, Cytiva

3-Jun	12:00 - 01:00 PM	Development and Clinical Applications of Cancer Immunotherapies	Single cell multiomic analysis of T-cell exhaustion	Pratip K. Chattopadhyay
3-Jun	01:00 - 02:00 PM	Immunotherapeutic Modalities	Gene manipulation in primary human immune cells: Successful strategies and applications for CRISPRko, RNAi and beyond	Verena Brucklacher-Waldert, PhD PhD in Neuroimmunology from the University of Tübingen, Germany, Manager Immunology Screening Services at Horizon Discovery
3-Jun	02:00 - 03:00 PM	Development and Clinical Applications of Cancer Immunotherapies	Dynamic Live Cell Imaging of Adherent and Immune Cells using CellASIC® ONIX2 Microfluidic Platform	Jun Park, PhD Senior Scientist, MilliporeSigma
3-Jun	03:00 - 04:00 PM	Immunotherapeutic Modalities	The roles of neoantigen peptides in personalized medicine	Samantha Zaroff, PhD Product Manager of Neoantigen Peptide Services at GenScript
3-Jun	04:00 - 05:00 PM		Microfluidic precision autostainer for fast multiplexed TSA-based immunofluorescence	Alexandre Kehren, M.Sc. Application Development Engineer
3-Jun	04:00 - 05:00 PM		Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology	Anushka Dikshit, PhD Application Scientist - Advanced Cell Diagnostics
3-Jun	12:00 - 12:05 AM	Immunotherapeutic Modalities	Checkpoint blockade-induced autoimmunity: Lessons from mouse models of type 1 diabetes	Tijana Martinov, PhD Postdoctoral Fellow, Laboratory of Dr. Philip Greenberg, Fred Hutchinson Cancer Research Center, Scholar of the Parker Institute for Cancer Immunotherapy
3-Jun	12:00 - 12:05 AM	Development and Clinical Applications of Cancer Immunotherapies	Clinical Development of Immunotherapy in Urothelial Cancer	Scot Niglio, MD Assistant Research Physician, National Institutes of Health, National Cancer Institute, Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology
3-Jun	12:00 - 12:05 AM	Immunotherapeutic Modalities	Deciphering the function of B cells in human cancer	Tullia C. Bruno, PhD Assistant Professor, University of Pittsburgh, Hillman Cancer Center
3-Jun	12:00 - 12:05 AM	Latest Trends in Immuno-Oncology	Define challenges of tissue-based biomarker development for Immuno-Oncology Therapy	Houssein Sater, MD Physician scientist at NCI (National Cancer Institute)

3-Jun	12:00 - 12:05 AM	Latest Trends in Immuno-Oncology	Microenvironment on Demand: A breakthrough technology for personalized cell therapy discoveries	Maithreyan Srinivasan Chief Scientific Officer, Scribe Biosciences
3-Jun	12:00 - 12:05 AM	Latest Trends in Immuno-Oncology	Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins	Shannon K. Oda, PhD Principal Investigator, Seattle Children's Research Institute, Assistant Professor, University of Washington School of Medicine
3-Jun	12:00 - 12:05 AM	Immunotherapeutic Modalities	Primary and Acquired Resistance to Cancer Immunotherapy	Leonardo Nissola, MD Clinical Scientist, The Parker Institute for Cancer Immunotherapy, and Former Medical Oncology Fellow at the University of Texas MD Anderson Cancer Center